AnaptysBio Inc
Open
SectorHealthcare
55.06 -1.22
Overview
Share price change
24h
Min
54.29
Max
56.19
Income | -102M -53M |
|---|---|
Sales | -83M 26M |
EPS | -1.34 |
Profit margin | -206.934 |
Employees | 104 |
EBITDA | -99M -31M |
Next Earnings | 15 Sept 2026 |
|---|
Market Cap | -295M 1.7B |
|---|---|
Previous open | 56.28 |
Previous close | 55.06 |
News Sentiment
By Acuity
36%
64%
100 / 339 Healthcare
AnaptysBio Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
AnaptysBio Inc Forecast
Sentiment
By Acuity
100 / 339 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About AnaptysBio Inc
AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.
